Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 8, 2022

Rhea-AI Summary

Tricida, Inc. (TCDA) will report its second quarter 2022 financial results after market close on August 8, 2022. A conference call is scheduled at 4:30 PM ET to discuss the results and business progress. Interested parties can access the call via webcast or dial in using the provided contact numbers. Tricida focuses on developing veverimer, an investigational drug aimed at slowing CKD progression in patients with metabolic acidosis. Currently, there are no FDA-approved therapies for this condition in CKD patients.

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on Monday, August 8, 2022. Tricida will host a webcast and conference call at 4:30 pm Eastern Time to discuss its second quarter financial results and business progress. The webcast or call may be accessed as follows:

Tricida Second Quarter Financial Results Conference Call
Monday, August 8, 2022
4:30 pm Eastern Time

	Webcast:	IR.Tricida.com
	Dial-in:	(800) 715-9871
	International:	(646) 307-1963
	Conference ID:	3576787

A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis and CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately 4.3 million patients with CKD in the United States. There are currently no therapies approved by the FDA to slow progression of kidney disease by correcting chronic metabolic acidosis in patients with CKD.

For more information about Tricida, please visit www.Tricida.com.

Contact:
Jackie Cossmon
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com

Source: Tricida, Inc.

FAQ

When will Tricida report its second quarter 2022 financial results?

Tricida will report its second quarter 2022 financial results on August 8, 2022.

What time is the Tricida conference call for financial results?

The Tricida conference call is scheduled for 4:30 PM ET on August 8, 2022.

How can I access the Tricida conference call?

You can access the Tricida conference call via webcast at IR.Tricida.com or by calling (800) 715-9871.

What is Tricida's main drug candidate?

Tricida's main drug candidate is veverimer, aimed at slowing CKD progression in patients with metabolic acidosis.

What clinical trial is Tricida currently conducting?

Tricida is conducting the VALOR-CKD clinical trial to assess veverimer's efficacy in slowing CKD progression.